$XBI $76.69 | -6%
Table of Contents:
Covid Updates
$PFE BNTX Pfizer and BioNTech Submit Application for U.S. Emergency Use Authorization for a COVID-19 Vaccine Booster Dose in Children 5 Through 11 Years of Age.
$NVAX -6% Novavax price target lowered at B. Riley amid demand uncertainty for COVID-19 shots.
Pipeline Updates
$EDIT -7% Editas Medicine Receives FDA Rare Pediatric Disease Designation for EDIT-301 for the Treatment of Beta Thalassemia
$EVFM -6% Evofem to Present New Research in Gynecological Health at the 2022 American College of Obstetricians and Gynecologists Annual Meeting.
$CTXR -2% Citius Pharmaceuticals Enrolls First Patient in Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids
$PRTA -14% Prothena Receives FDA Fast Track Designation for PRX012, a Next-Generation Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease.
$CLRB -6% Cellectar Biosciences Announces Positive DMC Review of Pivotal Trial of Iopofosine in Waldenstrom’s Macroglobulinemia.
$ARWR -7% Arrowhead Pharmaceuticals Initiates Phase 2 GATEWAY Study of Investigational ARO-ANG3 for Treatment of Homozygous Familial Hypercholesterolemia.
$GMDA -5% Gamida Cell Announces FDA Clearance of IND and Removal of Clinical Hold for NK Cell Therapy Candidate GDA-201.
$VERV -7% Verve Therapeutics Presents Comprehensive Analyses of Off-target Editing Risk for VERVE-101 at Precision Genome Engineering Keystone Symposia.
$GMDA -5% Gamida Cell Presents Updated Omidubicel Data During Best Abstract Award Session at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings.
Business Updates
$SCYX -4% SCYNEXIS Announces Closing of $45 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants.
$DCPH -7% Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants.
$SAVA +5% Letter To Science Editor of the New York Times.
$MOLN -17% Molecular Partners Provides Update on Ensovibep Following Novartis Quarterly Earnings Call. Molecular Partners to Regain Global Rights for MP0310 from Amgen.
$AMRN -2% Evofem to Present New Research in Gynecological Health at the 2022 American College of Obstetricians and Gynecologists Annual Meeting.
$EVAX -1% Evaxion to Utilize Personalis’ ImmunoID NeXT Platform® to Evaluate Efficacy of Combination Therapy for Late-Stage Melanoma.
$SLS -4% SELLAS Life Sciences Launches Expanded Access Program for Galinpepimut-S.
$ATHA -3% Athira Files Investor Presentation Highlighting Successful Execution of its Strategy and Highly Qualified Board and Leadership.
$AGRX -17% AGILE THERAPEUTICS ANNOUNCES 1-FOR-40 REVERSE STOCK SPLIT.
$AVDL +26% Avadel Pharmaceuticals Provides Comment on Recent Trading Activity.
$HALO -4% HALOZYME COMMENCES TENDER OFFER FOR ALL OUTSTANDING SHARES OF COMMON STOCK OF ANTARES PHARMA.
$MRKR +1% MARKER THERAPEUTICS ANNOUNCES ENTRY INTO SERVICES AGREEMENT WITH WILSON WOLF
$NKTX -10% NKARTA ANNOUNCES PRICING OF UPSIZED PUBLIC OFFERING OF COMMON STOCK ($15/sh).
$ERYP -23% Disposition of certain assets and inventory to Catalent.
Posted by DV
Comments